The combination of PARP inhibitors with immune checkpoint blockade represents a fascinating but selective avenue in the treatment of gynecologic cancers. These malignancies, particularly ovarian, endometrial, and cervical cancers, are significant contributors to cancer-related illness and death. The challenges stem from late diagnoses, high rates of relapse, and resistance to existing therapies. However, over the last ten years, two classes of drugs have significantly altered outcomes for specific patient populations: immune checkpoint inhibitors (which target PD-1/PD-L1) and PARP inhibitors. While both classes offer promising benefits, their most reliable efficacy is found in biomarker-defined subsets—such as dMMR/MSI-H for immunotherapy and BRCA/HRD for PARP inhibition.
Recent research indicates that these therapies may work well together on a biological level. For instance, PARP inhibition not only increases DNA damage but also activates innate immune responses through pathways like cGAS–STING, enhances interferon signaling, and boosts tumor immunogenicity. This effect could potentially be amplified when combined with PD-1/PD-L1 blockade.
Study Design and Methodology
This study presents a structured narrative review. The authors conducted a thorough search through databases such as MEDLINE, Embase, and ClinicalTrials.gov from January 1, 2015, to August 24, 2025, focusing on interventional trials assessing the use of a PARP inhibitor alongside an anti–PD-1/PD-L1 agent specifically for ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer.
Key Inclusion Criteria:
- Studies had to report at least one efficacy endpoint (overall response rate, progression-free survival, and/or overall survival) while ensuring safety was evaluated in a cohort exclusively focused on gynecologic cancers, comprising a minimum of 20 evaluable patients or any phase III trials.
- Trials involving a third non-cytotoxic agent, such as bevacizumab, were permitted.
- Investigational combinations that included concurrent cytotoxic chemotherapy were excluded to avoid confounding effects from overlapping side effects like myelosuppression.
- Ultimately, nine studies met the eligibility criteria, including one phase III trial and eight phase I/II trials.
Results
Ovarian Cancer: A Notable Area of Focus (Especially BRCA/HRD)
Among studies centered on recurrent ovarian cancer, the benefits linked to certain biological profiles, particularly BRCA/HRD, were notably strong:
- The combination of niraparib and pembrolizumab showed modest overall effectiveness, with more sustained responses observed in HRD-positive tumors.
- Olaparib combined with durvalumab demonstrated significant activity in cases of gBRCA platinum-sensitive relapse, aligning with the context of PARP-sensitive disease.
In some studies, adding bevacizumab appeared to enhance benefits for non-BRCA cohorts, supporting the notion of using non-cytotoxic triplet strategies based on immunomodulation and vascular normalization.
Frontline Maintenance: Randomized Evidence Lacks Support
A critical observation from the review highlights that in newly diagnosed ovarian cancer cases, the combination of PARP inhibitors and immune checkpoint inhibitors has not shown superior results:
- The maintenance therapy of rucaparib combined with nivolumab did not yield improved progression-free survival compared to rucaparib used alone. This discrepancy underscores the gap between early-phase clinical signals and outcomes seen in phase III trials within an unselected frontline population.
Endometrial Cancer: Overall Limited Activity, Signals Only in Selected Subgroups
In the context of predominantly pMMR or biomarker-agnostic endometrial cancer:
- The combinations of olaparib with durvalumab and talazoparib with avelumab exhibited modest activity, primarily benefiting biomarker-enriched groups (such as those with HRR alterations).
This trend aligns with broader findings that immunotherapy for endometrial cancer is most effective in dMMR/MSI-H cases, where checkpoint blockade is frequently beneficial.
Safety and Tolerability
The toxicities observed were consistent with expected effects associated with each drug class:
- Myelosuppression driven by PARP inhibitors (including anemia, thrombocytopenia, and neutropenia).
- Immune-related adverse effects typical of checkpoint inhibitors.
Overall, although most toxicities were manageable through standard treatment protocols, the combination approaches—especially triple therapies—could escalate the treatment burden and necessitate increased monitoring.
Insights
- The hypothesis of synergy between these therapies is biologically compelling, yet the clinical advantages are highly dependent on context.
- The strongest signals of efficacy are concentrated in ovarian cancer, particularly in settings involving BRCA/HRD and platinum sensitivity, where the inherent activity of the PARP backbone is apparent.
- There's currently no proven benefit for intensifying frontline maintenance, and existing randomized data does not endorse routine maintenance with PARP inhibitors and immune checkpoint inhibitors in unselected populations.
- In endometrial cancer, the combinations do not seem to offer broadly transformative results except for molecularly selected groups.
Key Takeaway Messages
- The most suitable indication is in ovarian cancer, especially for BRCA/HRD tumors, where selected non-BRCA cases might still gain from non-cytotoxic triplet strategies, like those including bevacizumab.
- The benefit of frontline maintenance in ovarian cancer remains unverified based on the phase III evidence reviewed here.
- For endometrial cancer, the effectiveness is modest and likely requires careful biomarker-guided selection.
- Future advancements in this field will hinge on enrolling patients based on biomarkers, choosing rational combinations, and optimizing treatment sequencing rather than applying broad, unselected strategies.
Conclusion
The integration of PD-1/PD-L1 blockade with PARP inhibition holds promise as a targeted strategy in gynecologic oncology. Current data reinforces this concept most robustly in the context of ovarian cancer, particularly where BRCA/HRD biology and platinum sensitivity suggest a solid foundation for PARP therapy. Conversely, the benefits of frontline maintenance remain undefined, and the impact on endometrial cancer appears limited outside specific molecular contexts. Moving forward, there is a pressing need for randomized trials enriched with biomarkers, clearer strategies for sequencing treatments, and regimens that account for tolerability to determine where this combined approach can truly revolutionize practice in the field.
